Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Inclusion Criteria

Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms
(MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:

   - Present for an AML-like treatment that could plausibly produce a complete remission
   (CR); for example intensive induction chemotherapy, low dose single agent
   chemotherapy, hypomethylation agent, or a similar therapy

   - Possibility to retrieve follow-up records from the collaborating institution or
   treating primary care physician

   - Patients with primary refractory or first relapse presenting for salvage chemotherapy
   will be allowed

   - Patients of 18 years of age or older, and are being treated by the adult AML service.

   - Able to speak and read English.

   - Willing and able to provide informed consent.

Exclusion Criteria

   - Patients of ≤17 years of age or who are 18 or older and receive treatment under the
   pediatric AML service.

   - Patients older than 80 years

   - Patients with <6 months projected survival due to active second malignancy or other
   medical problem.